Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Theratope((R)) vaccine (STn-KLH)
Autore:
Holmberg, LA; Sandmaier, BM;
Indirizzi:
Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA Univ Washington Seattle WA USA 98109 Div Clin Res, Seattle, WA 98109 USA Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA Univ WashingtonSeattle WA USA 98104 Med, Dept Med, Seattle, WA 98104 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 5, volume: 1, anno: 2001,
pagine: 881 - 891
SICI:
1471-2598(200109)1:5<881:TV(>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVE SPECIFIC IMMUNOTHERAPY; OVARIAN-CANCER PATIENTS; CELLULAR IMMUNE-RESPONSE; HIGH-DOSE CHEMOTHERAPY; PLUS DETOX ADJUVANT; SUPPRESSOR T-CELLS; SIALYL-TN; BREAST-CANCER; METASTATIC BREAST; MELANOMA PATIENTS;
Keywords:
breast cancer; cancer vaccine; colorectal cancer; immune responses; immunotherapy; ovarian cancer; pancreatic cancer; Sialo-Th; Theratope((R)) vaccine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Holmberg, LA Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100Fairview Ave,N D5-390, Seattle, WA 98109 USA Univ Washington 1100 Fairview Ave,N D5-390 Seattle WA USA 98109
Citazione:
L.A. Holmberg e B.M. Sandmaier, "Theratope((R)) vaccine (STn-KLH)", EXPERT OP B, 1(5), 2001, pp. 881-891

Abstract

Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have demonstrated that various cancer vaccines can stimulate antibody and cell mediated immune responses against tumour-associated antigens ([1-9]). Yet few studies have demonstrated convincing clinical responses. Sialyl-Tn (STn) is a carbohydrate associated with the MUC1 mucin on a number of human cancer cells and is associated with more aggressive disease. Consequently, STn is an ideal candidate for ASI therapy. Theratope((R)) vaccine is a cancer vaccine that was designed by Biomira, Inc. (Edmonton, Alberta, Canada) by incorporating a synthetic STn antigen that emulates the carbohydrate seen on human tumours. The clinical trials conducted to date with Theratope((R)) vaccine are outlined in this report. Overall, Theratope((R)) vaccine has been well-tolerated with minimal toxicity. The most common side effects have been induration and erythema at the site of injections. Both in a non-transplant setting following low doseiv. cyclophosphamide and high dose autologous transplant setting, there has been a trend toward Theratope((R)) vaccine decreasing the risk for relapse, prolonging the time to relapse and thus impacting on overall survival. The definitive Phase III trial comparing the outcome of patients with metastatic breast cancer receiving vaccinations with Theratope((R)) vaccine versus vaccination with the nonspecific immune stimulants Keyhole Limpet Hemocyanin (KLH) and Detox (TM) (-) B stable emulsion (Detox-B) (now called Enhanzyn (TM) Immunostimulant) was closed to enrolment on March 30, 2001. Over 1000 women with distant metastatic breast cancer were enrolled into the program.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 23:29:09